Heartfelt with Dr Melissa Walton-Shirley

View all posts »

Latest on atrial fibrillation with analysis of ROCKET AF (rivaroxaban) and POM 3 (fish oil supplements); SMART-AV on cardiac resynchronization; PFO closure in CLOSURE I

Nov 16, 2010 10:40 EST


Watch analysis and clinical implications of today’s late-breaking trials at American Heart Association (AHA) 2010 Scientific Sessions.

See:

SMART-AV: SmartDelay fails to outwit other CRT AV-delay-optimization approaches

Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial

CLOSURE I: No overall benefit, no reduction in stroke or TIA with PFO closure

Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds





« Previous Post
DES safety in BASKET-PROVE; ACT on contrast-induced nephropathy; dosing for clopidogrel nonresponders in GRAVITAS; TAMARIS on gene therapy
Nov 17, 2010 00:05 EST Next post »
Take the thrombin-inhibitor exam: Automatically win a million dollars if you get 100% correct!
Nov 15, 2010 23:37 EST



Your comments
Latest on atrial fibrillation with analysis of ROCKET AF (rivaroxaban) and POM 3 (fish oil supplements); SMART-AV on cardiac resynchronization; PFO closure in CLOSURE I
# 1 of 2
November 16, 2010 08:31 (EST)
Chan
Dr. Melissa, Rivoraxaban is an Factor Xa inhibitor, not a Direct Thrombin Inhibitor.
# 2 of 2
November 17, 2010 12:27 (EST)
Melissa

Thanks Chan. I apologize for the error and I appreciate your viewing and your post! I'm afraid I might have repeated that error in another post as well.  At least I'm consistent, though and apologize twice.

Melissa 


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access    
About Dr Melissa Walton-Shirley
Dr Walton-Shirley performs invasive cardiology, nuclear cardiology, and stress echocardiography in a private practice in Glasgow, KY.

Her chief medical interests are CHF/hypertrophic obstructive cardiomyopathy and the promotion of primary PCI for acute MI. Recently she played a significant role in helping to launch an ambitious pilot study of primary PCI in Kentucky, the Kentucky Primary Angioplasty Pilot Project. She has also participated in the TIMI 19, Duke-HF, NRMI, and CRUSADE trials and is proud to have been an advocate of the first smoke-free initiative in Kentucky (2011). She champions a smoke-free America.

Dr Walton-Shirley received her undergraduate degree at the University of Kentucky and went to medical school and did her residency and fellowship at the University of Louisville. She is married with two daughters. Her interests include singing, writing poetry and songs, fitness, and, of course, theheart.org.